Home › Hypertrophic Cardiomyopathy › Minnesota
Hypertrophic Cardiomyopathy clinical trials in Minnesota
3 studies for Hypertrophic Cardiomyopathy are looking for participants at sites in Minnesota.
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- Minneapolis Heart Institute Foundation, Minneapolis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05489705A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Imbria Investigational Site, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT07023614Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Mar 19, 2026 · NCT05836259From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.